WhiteLab Genomics Lands €23.2M to Turn AI-Designed Genetic Medicines Into Validated Therapies

French TechBio company WhiteLab Genomics has secured €23.2 million in new financing as it moves to expand the experimental validation of its AI-designed genomic medicine candidates. The Series B was led by AVP and backed by Omnes Capital, Yaday Health, Blast Club and the Debiopharm Innovation Fund. The round brings WhiteLab’s total funding to roughly $37 million.

Established in 2019, the Paris-headquartered company was created by David Del Bourgo, Lucia Cinque and Julien Cottineau. WhiteLab now operates across Paris, Boston and Montréal, combining artificial intelligence, computational biology and structural biology to tackle challenges in genomic medicine.

Its core technology, ALFRED, is designed to help researchers determine which molecular configurations are most likely to produce effective genomic medicines. Rather than relying entirely on repeated laboratory experimentation, the platform can computationally evaluate delivery systems and genetic payloads before promising candidates move into biological testing.

The technology covers both viral and non-viral delivery approaches, including adeno-associated viruses and lipid nanoparticles, as well as programmable DNA and RNA payloads. WhiteLab combines these computational designs with wet-lab and in-vivo validation, creating a feedback loop between AI predictions and biological results.

One of the company's notable results has involved developing AI-designed AAVs capable of reaching the brain following systemic administration. Work carried out with the Paris Brain Institute produced in-vivo results showing brain delivery while limiting detectable liver exposure, addressing one of the major challenges in developing therapies for diseases affecting the central nervous system.

WhiteLab is already working with organisations including Sanofi, Cytiva and Debiopharm, alongside academic institutions such as the Paris Brain Institute, Institut de la Vision, University of Massachusetts and Généthon. The company says it has around 15 revenue-generating partnerships with external biotechnology and pharmaceutical companies.

The fresh capital will allow WhiteLab to broaden its validation programmes beyond AAV-based therapies. The company plans to work further on non-viral delivery technologies and programmable synthetic promoters while building a larger portfolio of experimentally validated biological assets.

International growth is another priority. WhiteLab intends to strengthen its Boston operation to support partnerships with North American biopharma companies, increase its presence on the US West Coast and explore opportunities in Japan and South Korea.

The company's strategy is to stop at a point where genomic medicine candidates have accumulated meaningful preclinical evidence, then advance those assets independently or alongside pharmaceutical partners. Its technology could eventually support treatments targeting conditions ranging from neurological and rare diseases to cancer.